Hormone therapyFDA-approvedFirst-line
Relugolix
How it works
Blocks the production of androgens (male hormones) that fuel prostate cancer growth, slowing tumor growth.
Cancer types
Prostate Cancer— All patients
Efficacy
Studies show that relugolix can improve metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Prostate Cancer Study: Relugolix and SBRT Treatment | Prostate Cancer | phase-2 | — | Source → |
| Study of Relugolix in Patients with Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| New Oral Treatment for Advanced Prostate Cancer Shows Promise | Prostate Cancer | phase-3 | Relugolix was associated with a 54% reduction in the risk of major adverse cardiovascular events. | Source → |
| Potential New Side Effects of Cancer Treatment Relugolix | Prostate Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.